Graft-versus-host disease (GVHD): cross-border specialty drug access for international patients

Quick orientation

GVHD occurs in 30 to 70 percent of allogeneic hematopoietic stem cell transplant recipients depending on conditioning regimen and donor source. Chronic GVHD is a leading cause of late mortality after allo-HSCT.

Typical age of onset. Acute GVHD typically within 100 days of transplant; chronic GVHD typically beyond 100 days.

Severity tiers. Severity grading uses the modified Glucksberg scale (acute) or NIH consensus criteria (chronic). Severe cases are life-threatening.

Why specialty drugs for Graft-versus-host disease (GVHD) are hard to access internationally

Several recent FDA approvals for steroid-refractory acute and chronic GVHD, including JAK inhibitors and ROCK2 inhibitors, are not yet registered in many MENA and South Asian countries despite the substantial transplant programs there.

Treatments approved by the FDA

• Rezurock (belumosudil) — FDA approval: 2021. Mechanism: ROCK2 inhibitor for chronic GVHD. Route: Oral once daily. US WAC ballpark: Approximately USD 200,000 per year. Country pricing: UAE · India · Egypt · Jordan · Oman.
• Niktimvo (axatilimab-csfr) — FDA approval: 2024. Mechanism: CSF1R antagonist for chronic GVHD. Route: Intravenous infusion every 2 weeks. US WAC ballpark: Approximately USD 380,000 per year. Country pricing: Kuwait · Jordan · Lebanon.
• Ryoncil (remestemcel-L-rknd) — FDA approval: 2024. Mechanism: Allogeneic bone-marrow-derived mesenchymal stromal cell therapy for steroid-refractory acute pediatric GVHD. Route: Intravenous infusion twice weekly for 4 weeks. US WAC ballpark: Approximately USD 195,000 per course. Country pricing: Saudi Arabia · Qatar.

Cross-border pathways used for Graft-versus-host disease (GVHD)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Medical Tourism Access

What your physician needs to know

• Confirm acute versus chronic GVHD and severity grade.
• Document steroid-refractory status where required by label.
• Coordinate with transplant center and hematology team.
• Monitor for infections during immunosuppressive therapy.
• Ryoncil requires qualified administration centers.

Common questions

Can these therapies be combined?

Combination regimens are sometimes used under specialist guidance.

Are they available outside the US?

Registration varies. We confirm by destination.

Is Ryoncil approved for adult patients?

Currently FDA-approved for pediatric steroid-refractory acute GVHD.

How long does shipment take?

Five to fifteen business days for the oral and biologic products. Cell therapies require travel to a qualified center.

What documents are required?

Transplant physician's prescription, biopsy or NIH-criteria documentation of GVHD, and clinical summary.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Graft-versus-host disease (GVHD), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Graft-versus-host disease (GVHD)

Reserved for you.